帕罗西汀与阿米替林治疗躯体形式障碍对照研究  

A control study of paroxetive and amitriptyline in the treatment of somatoform disorders

作　　者：魏长礼 包琳[1] 洪贵子 穆小梅 

机构地区：[1]天水市精神病医院,甘肃天水741000

出　　处：《临床心身疾病杂志》2007年第2期106-107,共2页Journal of Clinical Psychosomatic Diseases

摘　　要：目的比较帕罗西汀与阿米替林治疗躯体形式障碍的疗效及安全性。方法将66例躯体形式障碍患者随机分为研究组(帕罗西汀组)36例,对照组(阿米替林组)30例。疗程6w。于治疗前及治疗2w、4w、6w末采用汉密顿抑郁量表、汉密顿焦虑量表评定临床疗效,副反应量表评定不良反应。结果治疗2w、4w、6w末,两组汉密顿抑郁量表、汉密顿焦虑量表总分及各因子评分与治疗前比较均有显著或极显著性下降(P<0.05或0.01),同期两组间比较均无显著性差异(P均>0.05)。研究组不良反应发生率较对照组低,且程度轻,差异有显著或极显著性(P<0.05或0.01)。结论帕罗西汀与阿米替林治疗躯体形式障碍疗效相当,但帕罗西汀的安全性较阿米替林高,依从性好。Objective To compare the curative effects and safety of paroxetive and amitriptyline in the treatment of somatoform disorders. Methods 66 patients with somatoform disorder were randomly divided into research（paroxetive, n = 36） and control（amitriptyline, n = 30） groups for 6 weeks. Before treatment and at the ends of the 2nd, 4th and 6th week of treatment, the clinical effects were assessed with the Hamilton Depression Scale（HAMD） and the Hamilton Anxiety Scale （HAMA）, and adverse effects with the Treatment Emergent Symptom Scale（TESS）, respectively. Results At the ends of the 2nd, 4th and 6th week, compared with pre-treatment the total scores of the HAMD or the HAMA and each factor＇s score decreased significantly or very for both groups（P〈0.05 or 0.01）, and in corresponding period there was no significant difference between the 2 groups（all P〉0. 05）. Incidence of the adverse effects was lower and milder in the research than in the control group, differences were significant or very（P〈0.05 or 0. 01）. Conclusion Paroxetive has therapeutic equivalence to amitriptyline, higher safety and better compliance in somatoform disorders.

关 键 词：帕罗西汀 阿米替林 躯体形式障碍 疗效 安全性 

分 类 号：R749.73[医药卫生—神经病学与精神病学]